Pig Kidney Xenotransplant
In October 2021, surgeons at NYU Langone Health successfully attached a genetically modified pig kidney to a brain-dead human patient, monitoring it function normally for 54 hours without immediate rejection—the most advanced xenotransplantation (cross-species organ transplant) demonstration and a potential solution to organ shortage crises.
The kidney came from a pig with 10 gene edits removing pig-specific antigens that trigger human immune rejection and adding human genes to improve compatibility. The organ produced urine and creatinine levels comparable to human kidneys, suggesting gene editing could overcome the immunological barriers that defeated previous xenotransplant attempts.
The announcement generated 20+ million impressions as transplant surgeons celebrated progress toward addressing the 100,000+ patient U.S. transplant waiting list, where 17 people die daily awaiting organs. Bioethicists debated animal welfare, religious concerns, and whether xenotransplantation should proceed to living patients.
In January 2022, University of Maryland surgeons transplanted a gene-edited pig heart into living patient David Bennett, who survived two months—the first xenotransplant into a living human since failed baboon liver and heart attempts in the 1980s-90s. Bennett’s death from unclear causes (possibly pig virus) highlighted safety challenges remaining before routine clinical use.
By 2023, researchers pursued refined gene editing (up to 69 edits), better immunosuppression protocols, and pathogen screening to prevent cross-species disease transmission. The progress validated xenotransplantation as a viable strategy for addressing organ shortages, with clinical trials anticipated by 2025-2027 if safety concerns could be resolved.